AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2019

Mar 11, 2019

30610_dirs_2019-03-11_601fbcf6-6f9d-458f-a662-67afb76c7728.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2019-03-08

Reporting Person: Bancel Stephane (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-08	Stock Option (Right to Buy)	$20.93	A	593592	Acquired	2029-03-08	Common Stock (593592)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.